Literature DB >> 7729901

Human immunoglobulin M paraproteins cross-reactive with Neisseria meningitidis group B polysaccharide and fetal brain.

F H Azmi1, A H Lucas, H L Spiegelberg, D M Granoff.   

Abstract

Three hundred fifty-nine serum samples from patients with immunoglobulin M (IgM) or IgG monoclonal gammopathies were tested for binding to the capsular polysaccharide (PS) of Neisseria meningitidis group B (MenB PS, poly-alpha[2-->8]-N-acetylneuraminic acid). Of 159 IgM paraproteins, 7 (4.4%) were positive, compared with 0 of 200 IgG paraproteins (P < 0.05). Since MenB PS reactivity was limited to the IgM paraproteins, the 159 IgM paraproteins were tested by enzyme-linked immunosorbent assay (ELISA) for reactivity with seven other bacterial PSs. None reacted with meningococcal A or C, Haemophilus influenzae type b, or Streptococcus pneumoniae type 3, 6, 14, or 23 PS. The specificity of the MenB PS-reactive antibodies was confirmed by demonstration of binding to N. meningitidis group B cells but not to a capsular PS-deficient mutant and by specific inhibition of binding to solid-phase MenB PS by soluble MenB PS in an ELISA. Five of five antibodies tested protected infant rats from bacteremia caused by Escherichia coli K1, an organism with a PS capsule that also is composed of poly-alpha[2-->8]-N-acetylneuraminic acid. Each of the seven MenB PS-reactive paraproteins had autoantibody activity as defined by binding to homogenates of calf brain in a radioimmunoassay. For six of the seven antibodies, binding to calf brain was inhibited by the addition of soluble MenB PS. Thus, approximately 4% of human IgM paraproteins have autoantibody activity to poly-alpha[2-->8]-N-acetylneuraminic acid, an antigen expressed in fetal brain and cross-reactive with the MenB capsular PS. The reason for this skewing of the IgM paraprotein repertoire toward reactivity with poly-alpha[2-->8]-N-acetylneuraminic acid antigenic determinants is unknown.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7729901      PMCID: PMC173242          DOI: 10.1128/iai.63.5.1906-1913.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  48 in total

Review 1.  Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias.

Authors:  G Merlini; M Farhangi; E F Osserman
Journal:  Semin Oncol       Date:  1986-09       Impact factor: 4.929

Review 2.  The spectrum of IgM monoclonal gammopathy in 430 cases.

Authors:  R A Kyle; J P Garton
Journal:  Mayo Clin Proc       Date:  1987-08       Impact factor: 7.616

3.  Peripheral neuropathy in macroglobulinemia: incidence and antigen-specificity of M proteins.

Authors:  E Nobile-Orazio; P Marmiroli; L Baldini; G Spagnol; S Barbieri; M Moggio; N Polli; E Polli; G Scarlato
Journal:  Neurology       Date:  1987-09       Impact factor: 9.910

4.  Cryptic cold agglutinin activity of monoclonal macroglobulins.

Authors:  W Pruzanski; H Jacobs; S Saito; E M Donnelly; L C Lui
Journal:  Am J Hematol       Date:  1987-10       Impact factor: 10.047

5.  Class-specific human bactericidal antibodies to capsular and noncapsular surface antigens of Neisseria meningitidis.

Authors:  L Skevakis; C E Frasch; J M Zahradnik; R Dolin
Journal:  J Infect Dis       Date:  1984-03       Impact factor: 5.226

6.  IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside.

Authors:  A A Ilyas; R H Quarles; T D MacIntosh; M J Dobersen; B D Trapp; M C Dalakas; R O Brady
Journal:  Proc Natl Acad Sci U S A       Date:  1984-02       Impact factor: 11.205

7.  Prevention and therapy of experimental Escherichia coli infection with monoclonal antibody.

Authors:  K S Kim; A S Cross; W Zollinger; J Sadoff
Journal:  Infect Immun       Date:  1985-12       Impact factor: 3.441

8.  Human monoclonal antibody with protective activity for Escherichia coli K1 and Neisseria meningitidis group B infections.

Authors:  H V Raff; D Devereux; W Shuford; D Abbott-Brown; G Maloney
Journal:  J Infect Dis       Date:  1988-01       Impact factor: 5.226

9.  A human monoclonal macroglobulin with specificity for alpha(2----8)-linked poly-N-acetyl neuraminic acid, the capsular polysaccharide of group B meningococci and Escherichia coli K1, which crossreacts with polynucleotides and with denatured DNA.

Authors:  E A Kabat; K G Nickerson; J Liao; L Grossbard; E F Osserman; E Glickman; L Chess; J B Robbins; R Schneerson; Y H Yang
Journal:  J Exp Med       Date:  1986-08-01       Impact factor: 14.307

10.  A monoclonal antibody against meningococcus group B polysaccharides distinguishes embryonic from adult N-CAM.

Authors:  G Rougon; C Dubois; N Buckley; J L Magnani; W Zollinger
Journal:  J Cell Biol       Date:  1986-12       Impact factor: 10.539

View more
  10 in total

1.  Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia.

Authors:  Fabio Ghiotto; Franco Fais; Angelo Valetto; Emilia Albesiano; Shiori Hashimoto; Mariella Dono; Hideyuki Ikematsu; Steven L Allen; Jonathan Kolitz; Kanti R Rai; Marco Nardini; Anna Tramontano; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

2.  Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine.

Authors:  Peter T Beernink; Jo Anne Welsch; Lee H Harrison; Arunas Leipus; Sheldon L Kaplan; Dan M Granoff
Journal:  J Infect Dis       Date:  2007-04-05       Impact factor: 5.226

3.  Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys.

Authors:  S J Devi; W D Zollinger; P J Snoy; J Y Tai; P Costantini; F Norelli; R Rappuoli; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

4.  Bactericidal antibody responses of juvenile rhesus monkeys immunized with group B Neisseria meningitidis capsular polysaccharide-protein conjugate vaccines.

Authors:  W D Zollinger; E E Moran; S J Devi; C E Frasch
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

5.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

6.  Differences in surface expression of NspA among Neisseria meningitidis group B strains.

Authors:  G R Moe; S Tan; D M Granoff
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

7.  Sequential immunization with vesicles prepared from heterologous Neisseria meningitidis strains elicits broadly protective serum antibodies to group B strains.

Authors:  Gregory R Moe; Patricia Zuno-Mitchell; Samantha N Hammond; Dan M Granoff
Journal:  Infect Immun       Date:  2002-11       Impact factor: 3.441

8.  Antibody responses to the capsular polysaccharide of Neisseria meningitidis serogroup B in patients with meningococcal disease.

Authors:  D M Granoff; S K Kelsey; H A Bijlmer; L Van Alphen; J Dankert; R E Mandrell; F H Azmi; R J Scholten
Journal:  Clin Diagn Lab Immunol       Date:  1995-09

9.  Streptococcus mitis phage-encoded adhesins mediate attachment to {alpha}2-8-linked sialic acid residues on platelet membrane gangliosides.

Authors:  Jennifer Mitchell; Paul M Sullam
Journal:  Infect Immun       Date:  2009-06-08       Impact factor: 3.441

10.  Inadequacy of colominic acid as an absorbent intended to facilitate use of complement-preserved baby rabbit serum in the Neisseria meningitidis serogroup B serum bactericidal antibody assay.

Authors:  Jamie Findlow; Ann Holland; Diana Martin; Philipp Oster; Paul Balmer; Ray Borrow
Journal:  Clin Vaccine Immunol       Date:  2007-03-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.